Bioprinting & Tissue Regeneration in Focus: Center for Engineering Complex Tissues Opens This Weekend Thanks to NIH Grant
Even the most cutting-edge research needs an economic boost to keep going, and the National Institutes of Health (NIH) often provides this boost in the form of grants. The NIH has awarded grants to several research efforts centered around 3D printing technology, including Northeastern University’s work with 3D magnetic printing to make neonatal catheters, the University of Texas at Arlington’s materials development for 3D printed pediatric blood vessels, and 3D printed scaffolds for studying bone cancer tumors by Rice University researchers. Recently, a team of bioengineers from Rice University, Wake Forest University, and the University of Maryland received a $6.25 million grant from the NIH, which will be used to establish the Center for Engineering Complex Tissues (CECT).Tissue engineering is also known as regenerative medicine, and works to make functional constructs that are able to maintain, improve, or fully restore organs and tissues that have been damaged. This type of medicine uses the natural healing powers of the human body as the basis for enhanced healing, and combines biodegradable templates, cells, and biologically active molecules into bioprinted scaffolds for the cells to grow into fully functioning tissues; 3D printed scaffolds are a topic we often cover here at 3DPrint.com as the technology lends itself well to creating complex and customizable bio-compatible structures.
Rice University’s principal investigator for the five-year grant is Antonios Mikos, who was also on the research team for the university’s 3D printed scaffolds and bone cancer work. Mikos is the Louis Calder Professor of Bioengineering and Chemical and Biomolecular Engineering, the director of the Center for Excellence in Tissue Engineering, and also the director of the J.W. Cox Laboratory for Biomedical Engineering; his CECT co-investigator is David Scott, the Noah Harding Professor of Statistics.
“The CECT establishes Rice as a premier institution in tissue engineering and regenerative medicine. We have made tremendous progress alongside our colleagues at the Texas Medical Center. The CECT is a wonderful recognition of all of our collaborative efforts and presents an exciting beginning as we continue to work as a community on new technologies to improve health care,” said Mikos.
Co-principal investigators for Wake Forest’s technology research and development work for the CECT are Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine and the chair of the Department of Urology at Wake Forest Baptist Medical Center, and James Yoo, professor, associate director, and chief scientific officer at the Wake Forest Institute for Regenerative Medicine.
Atala said, “We are proud to be part of this collaborative effort to advance the field of 3D bioprinting. We believe bioprinting represents one of the most promising strategies for increasing the number of patients who can benefit from replacement tissues and organs.”
CECT researchers will work with other experts across the US on six collaborative projects and six service projects. The service projects, which will be executed with teams at the University of Maryland, Emory University, Columbia University, Stanford University, Georgia Tech, Texas A&M University, and Synthasome Inc., will bring the technologies CECT is working on to broader applications and additional projects.
CECT co-principal investigator John Fisher, the Fischell Family Distinguished Professor and chair of the Fischell Department of Bioengineering at the University of Maryland, said, “CECT will become a national hub for regenerative medicine through which leading experts of all areas of bioengineering, tissue engineering and additive manufacturing can work collaboratively to advance human health. Anyone in the world will have the opportunity to reach out to us to work in our labs. In this way, CECT will foster a two-way transfer of science to spur innovations that can shape the way bone, tissue and organ defects are treated or repaired.”
Mikos explained that the collaborative projects will make for a combined, coordinated technology testing environment, where researchers can give each other feedback in order to solve various biomedical problems, which will foster the development of new and improved technology, as well as new CECT strategies. Experts at the Mayo Clinic, the University of Toronto, the University of Pittsburgh, Harvard University, and the University of Pennsylvania will work together on these collaborative projects.
“The great education opportunity the center allows is a tremendous draw for people to come here and learn about the techniques Rice is working on. By helping the community develop this expertise, we will continue to build the Advances in Tissue Engineering continuing-education course Rice has been committed to for more than 25 years,” said Mikos.
The new CECT will take tissue engineering from the laboratory to the clinic beginning April 15, and develop new technologies, while also acting as a collaborative hub for the biomaterials experts, engineers, and surgeons working on regenerative medicine. The ultimate goal is to take current 3D printing and tissue engineering technologies, and upgrade them into improved platforms for everyday use in biomedical device and regenerative medicine development, and give the millions of people suffering from pain and limited mobility due to orthopedic defects a better quality of life. In addition to the twelve collaborative and service projects, the center will also be producing tissue-engineering constructs that have transplantation capabilities. Experts at each of the CECT’s three main institutions will develop a core technology for this effort:
- Rice University will focus on bioprinting for complex scaffold fabrication
- Wake Forest University will concentrate on bioprinting patterns for cell-laden constructs
- University of Maryland will work on 3D printed bioreactors for cell cultures
Mikos said, “The CECT is unique as it focuses both on the engineering of complex tissues and on the growing field of bioprinting. This grant is a great opportunity and responsibility to further develop the field and move it to the clinic.”
Discuss in the NIH forum at 3DPB.com.[Sources: Rice University, University of Maryland]
You May Also Like
Dream M&As: 3D Printing Mergers and Acquisitions We’d Like to See in 2021, Part 3
Inspired in part by the acquisition of EnvisionTEC by Desktop Metal, of 3D Hubs by ProtoLabs, and of Origin by Stratasys, we’ve been brainstorming about the newly hot 3D printing stocks and renewed interest...
3D Printing News Briefs, January 23, 2021: CADENAS, BCN3D, ExOne & AMGTA, 6K
We’ve got some business news for you in this weekend edition of 3D Printing News Briefs! CADENAS and BCN3D are both reporting good news from 2020, and ExOne has just...
CEO Meddah Hadjar to Leave SLM Solutions
SLM Solutions (AM3D.DE) has announced that its CEO, Meddah Hadjar, will not be extending his contract with the company at the end of January 2021. The company has stated the...
Dream M&As: 3D Printing Mergers and Acquisitions We’d Like to See in 2021, Part 2
Inspired in part by the acquisition of EnvisionTEC by Desktop Metal and of Origin by Stratasys, we’ve been brainstorming about the newly hot 3D printing stocks and renewed interest from investors in our markets. Is 2021 going...
View our broad assortment of in house and third party products.